The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

George R. Blumenschein

Department of Thoracic/Head and Neck Medical Oncology

The University of Texas MD Anderson Cancer Center

Houston

TX 77030

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2003 - 2012
  • The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. 2010
  • The M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, USA. 2009

References

  1. Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy. Blumenschein, G.R., Mills, G.B., Gonzalez-Angulo, A.M. J. Clin. Oncol. (2012) [Pubmed]
  2. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. Blumenschein, G.R., Ciuleanu, T., Robert, F., Groen, H.J., Usari, T., Ruiz-Garcia, A., Tye, L., Chao, R.C., Juhasz, E. J. Thorac. Oncol (2012) [Pubmed]
  3. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Blumenschein, G.R., Kabbinavar, F., Menon, H., Mok, T.S., Stephenson, J., Beck, J.T., Lakshmaiah, K., Reckamp, K., Hei, Y.J., Kracht, K., Sun, Y.N., Sikorski, R., Schwartzberg, L. Ann. Oncol. (2011) [Pubmed]
  4. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. Blumenschein, G.R., Paulus, R., Curran, W.J., Robert, F., Fossella, F., Werner-Wasik, M., Herbst, R.S., Doescher, P.O., Choy, H., Komaki, R. J. Clin. Oncol. (2011) [Pubmed]
  5. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Blumenschein, G.R., Reckamp, K., Stephenson, G.J., O'Rourke, T., Gladish, G., McGreivy, J., Sun, Y.N., Ye, Y., Parson, M., Sandler, A. Clin. Cancer Res. (2010) [Pubmed]
  6. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. Blumenschein, G.R., Gatzemeier, U., Fossella, F., Stewart, D.J., Cupit, L., Cihon, F., O'Leary, J., Reck, M. J. Clin. Oncol. (2009) [Pubmed]
  7. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Blumenschein, G.R., Kies, M.S., Papadimitrakopoulou, V.A., Lu, C., Kumar, A.J., Ricker, J.L., Chiao, J.H., Chen, C., Frankel, S.R. Invest. New. Drugs (2008) [Pubmed]
  8. Sorafenib in lung cancer: clinical developments and future directions. Blumenschein, G. J. Thorac. Oncol (2008) [Pubmed]
  9. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein, G.R., Khuri, F.R., von Pawel, J., Gatzemeier, U., Miller, W.H., Jotte, R.M., Le Treut, J., Sun, S.L., Zhang, J.K., Dziewanowska, Z.E., Negro-Vilar, A. J. Clin. Oncol. (2008) [Pubmed]
  10. Integration of targeted therapies in gemcitabine chemotherapy regimens. Blumenschein, G.R., Herbst, R.S. Clin. Lung. Cancer (2003) [Pubmed]
 
WikiGenes - Universities